Company Update: Amgen Inc. (NASDAQ:AMGN) – Ahead of the Bell: Amgen’s cholesterol drug

November 20, 2013 at 09:24 AM EST

[AP] – Amgen said Tuesday that an experimental drug reduced patients’ “bad” cholesterol levels by half in a yearlong study. The company said patients who took the drug, called evolocumab, and standard … . . . → Read More: Company Update: Amgen Inc. (NASDAQ:AMGN) – Ahead of the Bell: Amgen’s cholesterol drug Similar posts: Merck & Co. Inc. (NYSE:MRK) – Merck invests $107 million in China drug plant Amgen Inc. (NASDAQ:AMGN) – Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013 Johnson & Johnson (NYSE:JNJ) – U.S. guidelines expand potential uses of J&J TB drug

Amgen Inc. (NASDAQ:AMGN) [AP] – Amgen said Tuesday that an experimental drug reduced patients’ “bad” cholesterol levels by half in a yearlong study. The company said patients who took the drug, called evolocumab, and standard …
Read more on this.

Amgen Inc. (AMGN), valued at $87.37B, opened at $115.36.
… [visit site to read more]